Review for 10.1186/s12876-020-01196-0 (2020)

Reviewer’s report
Title: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors
for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
Version: 0 Date: 14 Jan 2020
Reviewer: Kaushal Madan
Reviewer's report:
1. In the methods section it should be written that it is a retrospective study. 
2. The mean age of the patients were 57 years, which is a bit surprising. What was the suspected
duration of infection in these patients? Is it that they were infected for along period of time and were
waiting for DAAs to get treated.?
3. The authors should also mention the dose modifications if any done In patients with CKD.
4. Among treatment experienced patients what were the treatment regimens used? Peg IFN based or
Sos + Riba?
5. Table number 4 is irrelevant for getups 2 and 4 because of small number of patients in the subgroup,
so this should be deleted.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
Yes
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
Yes
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further
assessment in your comments to the editors.
I am able to assess the statistics
Quality of written English
Please indicate the quality of language in the manuscript:
Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
I declare that I have nor competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named report
including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments
to the editors, which will not be published.
I agree to the open peer review policy of the journal